Department of Surgery, Yale University School of Medicine, Yale New Haven Hospital, New Haven, Connecticut 06520-8062, USA.
Tissue Eng Part B Rev. 2010 Jun;16(3):341-50. doi: 10.1089/ten.TEB.2009.0527.
Previous studies have demonstrated the benefits of cell seeding in the construction of tissue-engineered vascular grafts (TEVG). However, seeding methods are diverse and no method is clearly superior in either promoting seeding efficiency or improving long-term graft function. As we head into an era during which a variety of different TEVG are under investigation in clinical trials around the world, it is important to consider the regulatory issues surrounding the translation of these technologies. In this review, we summarize important advances in the field of vascular tissue engineering, with particular attention on cell-seeding techniques for TEVG development and special emphasis placed on regulatory issues concerning the clinical translation of these various methods.
先前的研究已经证明了细胞接种在构建组织工程血管移植物（TEVG）中的益处。然而，接种方法多种多样，没有一种方法在促进接种效率或改善长期移植物功能方面明显具有优势。随着我们进入一个世界各地的临床试验正在研究各种不同的 TEVG 的时代，重要的是要考虑这些技术转化所涉及的监管问题。在这篇综述中，我们总结了血管组织工程领域的重要进展，特别关注 TEVG 开发的细胞接种技术，并特别强调了这些各种方法临床转化的监管问题。
